Does the media refer more to VALN or RARE?

In the previous week, Ultragenyx Pharmaceutical had 1 more articles in the media than Valneva. MarketBeat recorded 6 mentions for Ultragenyx Pharmaceutical and 5 mentions for Valneva. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Valneva's score of 0.38 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VALN or ADPT?

In the previous week, Valneva and Valneva both had 5 articles in the media. Adaptive Biotechnologies' average media sentiment score of 1.42 beat Valneva's score of 0.38 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VALN or KOD more profitable?

Kodiak Sciences has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Valneva's return on equity of -107.63% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% Kodiak Sciences N/A -253.85% -81.48%

Does the media refer more to VALN or KOD?

In the previous week, Valneva had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 5 mentions for Valneva and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat Valneva's score of 0.38 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, VALN or ZLAB?

Valneva has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 2.68 -$130.33M -$1.87 N/A Zai Lab $460.16M 4.23 -$175.54M -$1.62 N/A

Is VALN or ZLAB more profitable?

Zai Lab has a net margin of -39.29% compared to Valneva's net margin of -88.87%. Zai Lab's return on equity of -24.32% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% Zai Lab -39.29% -24.32% -15.52%

Does the media favor VALN or ZLAB?

In the previous week, Valneva had 2 more articles in the media than Zai Lab. MarketBeat recorded 5 mentions for Valneva and 3 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.62 beat Valneva's score of 0.38 indicating that Zai Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, HCM or VALN?

HUTCHMED has higher revenue and earnings than Valneva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 3.60 $456.91M N/A N/A Valneva $197.56M 2.68 -$130.33M -$1.87 N/A

Is HCM or VALN more profitable?

HUTCHMED has a net margin of 0.00% compared to Valneva's net margin of -88.87%. HUTCHMED's return on equity of 0.00% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Valneva -88.87% -107.63% -33.02%

Does the media prefer HCM or VALN?

In the previous week, Valneva had 3 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Valneva and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.31 beat Valneva's score of 0.38 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Valneva (VALN) Competitors

$5.58 -0.05 (-0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$5.56 -0.01 (-0.27%)

As of 04:10 PM Eastern

Compare

VALN vs. RARE, ADPT, KOD, ZLAB, and HCM

Should you buy Valneva stock or one of its competitors? MarketBeat compares Valneva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Valneva include Ultragenyx Pharmaceutical (RARE), Adaptive Biotechnologies (ADPT), Kodiak Sciences (KOD), Zai Lab (ZLAB), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.

How does Valneva compare to Ultragenyx Pharmaceutical?

Valneva (NASDAQ:VALN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Valneva currently has a consensus target price of $11.98, suggesting a potential upside of 114.61%. Ultragenyx Pharmaceutical has a consensus target price of $59.56, suggesting a potential upside of 165.79%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Valneva has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.68	-$130.33M	-$1.87	N/A
Ultragenyx Pharmaceutical	$673M	3.28	-$575M	-$6.11	N/A

11.4% of Valneva shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valneva has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

Valneva has a net margin of -88.87% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Valneva's return on equity of -107.63% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

In the previous week, Ultragenyx Pharmaceutical had 1 more articles in the media than Valneva. MarketBeat recorded 6 mentions for Ultragenyx Pharmaceutical and 5 mentions for Valneva. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Valneva's score of 0.38 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ultragenyx Pharmaceutical beats Valneva on 9 of the 17 factors compared between the two stocks.

How does Valneva compare to Adaptive Biotechnologies?

Valneva (NASDAQ:VALN) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

In the previous week, Valneva and Valneva both had 5 articles in the media. Adaptive Biotechnologies' average media sentiment score of 1.42 beat Valneva's score of 0.38 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.4% of Valneva shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Adaptive Biotechnologies has higher revenue and earnings than Valneva. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.68	-$130.33M	-$1.87	N/A
Adaptive Biotechnologies	$276.98M	9.24	-$59.50M	-$0.33	N/A

Valneva has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.15, meaning that its share price is 115% more volatile than the broader market.

Adaptive Biotechnologies has a net margin of -16.82% compared to Valneva's net margin of -88.87%. Adaptive Biotechnologies' return on equity of -40.06% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

Valneva presently has a consensus price target of $11.98, suggesting a potential upside of 114.61%. Adaptive Biotechnologies has a consensus price target of $19.57, suggesting a potential upside of 22.40%. Given Valneva's higher possible upside, analysts plainly believe Valneva is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Adaptive Biotechnologies beats Valneva on 12 of the 15 factors compared between the two stocks.

How does Valneva compare to Kodiak Sciences?

Valneva (NASDAQ:VALN) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Valneva presently has a consensus price target of $11.98, indicating a potential upside of 114.61%. Kodiak Sciences has a consensus price target of $42.14, indicating a potential upside of 24.43%. Given Valneva's higher possible upside, analysts plainly believe Valneva is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Valneva has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

Kodiak Sciences has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Valneva's return on equity of -107.63% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Kodiak Sciences	N/A	-253.85%	-81.48%

In the previous week, Valneva had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 5 mentions for Valneva and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat Valneva's score of 0.38 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Valneva has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.68	-$130.33M	-$1.87	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

11.4% of Valneva shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 45.9% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Valneva beats Kodiak Sciences on 8 of the 15 factors compared between the two stocks.

How does Valneva compare to Zai Lab?

Valneva (NASDAQ:VALN) and Zai Lab (NASDAQ:ZLAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Valneva has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Valneva has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.68	-$130.33M	-$1.87	N/A
Zai Lab	$460.16M	4.23	-$175.54M	-$1.62	N/A

In the previous week, Valneva had 2 more articles in the media than Zai Lab. MarketBeat recorded 5 mentions for Valneva and 3 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.62 beat Valneva's score of 0.38 indicating that Zai Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zai Lab has a net margin of -39.29% compared to Valneva's net margin of -88.87%. Zai Lab's return on equity of -24.32% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Zai Lab	-39.29%	-24.32%	-15.52%

Valneva currently has a consensus target price of $11.98, indicating a potential upside of 114.61%. Zai Lab has a consensus target price of $45.83, indicating a potential upside of 166.94%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts plainly believe Zai Lab is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

11.4% of Valneva shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Zai Lab beats Valneva on 12 of the 17 factors compared between the two stocks.

How does Valneva compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Valneva had 3 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Valneva and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.31 beat Valneva's score of 0.38 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HUTCHMED has a net margin of 0.00% compared to Valneva's net margin of -88.87%. HUTCHMED's return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Valneva	-88.87%	-107.63%	-33.02%

HUTCHMED has higher revenue and earnings than Valneva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.60	$456.91M	N/A	N/A
Valneva	$197.56M	2.68	-$130.33M	-$1.87	N/A

HUTCHMED presently has a consensus target price of $16.80, suggesting a potential upside of 48.54%. Valneva has a consensus target price of $11.98, suggesting a potential upside of 114.61%. Given Valneva's higher possible upside, analysts clearly believe Valneva is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

HUTCHMED has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Valneva has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Summary

HUTCHMED beats Valneva on 9 of the 15 factors compared between the two stocks.

Get Valneva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VALN vs. The Competition

Export

Metric	Valneva	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$529.49M	$7.86B	$6.25B	$12.42B
Dividend Yield	N/A	2.56%	2.69%	5.29%
P/E Ratio	-2.98	15.39	22.29	24.19
Price / Sales	2.68	5.69	581.44	138.36
Price / Cash	N/A	17.23	42.31	57.88
Price / Book	4.01	3.53	9.84	6.72
Net Income	-$130.33M	$224.05M	$3.57B	$337.19M
7 Day Performance	-11.99%	-1.11%	-1.17%	0.48%
1 Month Performance	4.30%	0.31%	3.84%	5.06%
1 Year Performance	-10.00%	-0.30%	27.39%	34.27%

Valneva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VALN Valneva	2.399 of 5 stars	$5.58 -0.9%	$11.98 +114.6%	-12.2%	$529.49M	$197.56M	N/A	700	Analyst Upgrade
RARE Ultragenyx Pharmaceutical	2.8137 of 5 stars	$23.26 -0.6%	$59.88 +157.4%	-39.7%	$2.29B	$673M	N/A	1,371	Positive News Insider Trade
ADPT Adaptive Biotechnologies	3.2303 of 5 stars	$14.09 +1.5%	$19.57 +38.9%	+58.5%	$2.25B	$276.98M	N/A	790	Positive News
KOD Kodiak Sciences	2.6223 of 5 stars	$35.91 -0.9%	$42.14 +17.4%	+822.8%	$2.25B	N/A	N/A	90
ZLAB Zai Lab	3.1608 of 5 stars	$18.40 -1.1%	$45.83 +149.1%	-45.0%	$2.09B	$460.16M	N/A	1,784

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VALN) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valneva (VALN) Competitors

VALN vs. RARE, ADPT, KOD, ZLAB, and HCM

How does Valneva compare to Ultragenyx Pharmaceutical?

Summary

How does Valneva compare to Adaptive Biotechnologies?

Summary

How does Valneva compare to Kodiak Sciences?

Summary

How does Valneva compare to Zai Lab?

Summary

How does Valneva compare to HUTCHMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN vs. The Competition

Valneva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valneva (VALN) Competitors

VALN vs. RARE, ADPT, KOD, ZLAB, and HCM

How does Valneva compare to Ultragenyx Pharmaceutical?

Do analysts rate VALN or RARE?

Which has preferable earnings & valuation, VALN or RARE?

Do insiders and institutionals hold more shares of VALN or RARE?

Which has more volatility and risk, VALN or RARE?

Is VALN or RARE more profitable?

Does the media refer more to VALN or RARE?

Summary

How does Valneva compare to Adaptive Biotechnologies?

Does the media refer more to VALN or ADPT?

Do institutionals & insiders hold more shares of VALN or ADPT?

Which has stronger valuation & earnings, VALN or ADPT?

Which has more risk & volatility, VALN or ADPT?

Is VALN or ADPT more profitable?

Do analysts rate VALN or ADPT?

Summary

How does Valneva compare to Kodiak Sciences?

Do analysts prefer VALN or KOD?

Which has more risk & volatility, VALN or KOD?

Is VALN or KOD more profitable?

Does the media refer more to VALN or KOD?

Which has better earnings and valuation, VALN or KOD?

Do insiders and institutionals believe in VALN or KOD?

Summary

How does Valneva compare to Zai Lab?

Which has more risk & volatility, VALN or ZLAB?

Which has better valuation & earnings, VALN or ZLAB?

Does the media favor VALN or ZLAB?

Is VALN or ZLAB more profitable?

Do analysts recommend VALN or ZLAB?

Do insiders & institutionals believe in VALN or ZLAB?

Summary

How does Valneva compare to HUTCHMED?

Does the media prefer HCM or VALN?

Is HCM or VALN more profitable?

Which has stronger valuation and earnings, HCM or VALN?

Do analysts rate HCM or VALN?

Do insiders and institutionals hold more shares of HCM or VALN?

Which has more risk & volatility, HCM or VALN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN vs. The Competition

Valneva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools